Atossa Therapeutics, Inc.’s Post

With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers

👏👏Take another look at our #HighlyCitedPaper by Vivek K. Kashyap et al:" Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics" Paper link: https://shorturl.at/sCJPZ

Come join us on April 17th at 9am at the Colonnade Hotel in Boston, MA at the 4th Fc Mediated Function Summit and learn about how to incorporate our platform in order to develop safer more efficacious monoclonal therapeutics. #mAbtherapeutics #Fceffectorfuntion #Fcmediatedfunctionsummit

Back-to-back development candidates progressing into the clinic is no mean feat! Following on the footsteps of VYN201 which progressed into Phase 2b last month; this week we are delighted to share that dosing of the first participants in the Phase 1a trial of VYN202 has taken place. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases. VYN202 was discovered by the team at Tay Therapeutics before being licensed to VYNE Therapeutics who are leading clinical development. Top-line data is expected in the second half of 2024. https://lnkd.in/ePG4eb7V https://lnkd.in/eGtRw7Ty

The Future of Exosome Based Therapeutics: Key Clinical Updates ZEO ScientifiX™ invites you to a LIVE Webinar on The Future of Exosome Based Therapeutics with Dr. George Shapiro, MD https://lnkd.in/g5pnyr42

Thoughts on this? >> Halia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #productmarketing #pharmaceutical

Thoughts on this? >> Halia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #pharma #productmarketing

Join the upcoming Fierce Pharma webinar, “Innovative Therapeutics: Challenges and Opportunities in Developing Drug Combinations,” at 11 am ET on Oct. 15 hosted by Clarivate’s Mike Ward. This session will explore the complexities of combination drug therapies, offering insights into optimizing dosing regimens, mitigating adverse drug interactions, and navigating regulatory pathways. https://bit.ly/3XUmaa1 Hear from industry leaders at Clarivate, iOnctura, NeuroSense Therapeutics, Olema Oncology, and Takeda as they discuss groundbreaking approaches to treating complex diseases through drug combinations. #DrugDevelopment #Webinar

#Theranostics is a promising future treatment for many types of #cancer. Stop by Michael Veronesi, M.D., Ph.D.'s presentation at #AAPS2024 to learn how this personalized treatment can be applied to #BrainTumors 🧠 American Association of Pharmaceutical Scientists (AAPS) | @aapscomms #MolecularImaging

CONFERENCE UPDATE: The abstract is available for Repare Therapeutics' presentation at ESMO GI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI. Learn more here: https://lnkd.in/ebPvugmb #precisiononcology #syntheticlethality #clinicaltrials